Synergizing Immune Effectors and Transcriptional Modulation for Enhanced Type-I Interferon Therapy in MPNs (21)

• Subject Area: Immunology
• Term: since 2022
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 318346496

Interferon alpha-2 (IFN-) is an approved therapy for myeloproliferative neoplasms (MPNs), but its mechanisms of action remain poorly understood. During the previous funding period, we demonstrated that the immune system plays a central role in mediating IFN- efficacy. In this project, we investigate how the immunomodulatory effects of IFN- integrate with endogenous activation of interferon-stimulated genes (ISGs) with the ultimate goal of developing more targeted treatment strategies for MPN patients.

• DFG Programme: Collaborative Research Centres
• Subproject of: SFB 1292: Targeting convergent mechanisms of inefficient immunity in tumors and chronic infections
• Applicant Institution: Johannes Gutenberg-Universität Mainz
• Project Heads: Dr. Sabine Muth; Professor Dr. Markus P. Radsak, until 12/2025; Dr. Daniel Sasca